Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Quest Diagnostics Incorporated

Healthcare US DGX

200.42USD
3.21(1.63%)

Last update at 2026-06-09T16:00:00Z

Day Range

196.99201.28
LowHigh

52 Week Range

162.47212.58
LowHigh

Fundamentals

  • Previous Close 197.21
  • Market Cap22759.44M
  • Volume142132
  • P/E Ratio22.43
  • Dividend Yield-%
  • EBITDA2175.00M
  • Revenue TTM11035.00M
  • Revenue Per Share TTM99.41
  • Gross Profit TTM 3678.00M
  • Diluted EPS TTM9.14

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 1360.00M 1194.00M 1130.00M 1235.00M 2599.00M
Minority interest -54.00000M -50.00000M -56.00000M -69.00000M -85.00000M
Net income 992.00M 871.00M 854.00M 946.00M 1995.00M
Selling general administrative 1920.00M 1770.00M 1798.00M 1818.00M 1727.00M
Selling and marketing expenses - - - - -
Gross profit 3523.00M 3244.00M 3053.00M 3433.00M 4209.00M
Reconciled depreciation 570.00M 493.00M 446.00M 437.00M 408.00M
Ebit 1624.00M 1401.00M 1262.00M 1428.00M 2381.00M
Ebitda 2194.00M 1894.00M 1262.00M 1810.00M 3158.00M
Depreciation and amortization 570.00M 493.00M 439.00M 382.00M 777.00M
Non operating income net other - - - -11.00000M 447.00M
Operating income 1603.00M 1346.00M 1262.00M 1428.00M 2381.00M
Other operating expenses 9432.00M 8526.00M 7990.00M 8455.00M 8407.00M
Interest expense 264.00M 226.00M 152.00M 138.00M 151.00M
Tax provision 314.00M 273.00M 204.00M 264.00M 597.00M
Interest income 264.00M 25.00M 9.00M 138.00M 151.00M
Net interest income -264.00000M -201.00000M -144.00000M -138.00000M -151.00000M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 314.00M 273.00M -248.00000M 264.00M 597.00M
Total revenue 11035.00M 9872.00M 9252.00M 9883.00M 10788.00M
Total operating expenses 1920.00M 1898.00M 1642.00M 2005.00M 1828.00M
Cost of revenue 7512.00M 6628.00M 6199.00M 6450.00M 6579.00M
Total other income expense net -243.00000M -152.00000M -132.00000M -193.00000M 218.00M
Discontinued operations - - - - -
Net income from continuing ops 1046.00M 921.00M 819.00M 1015.00M 2080.00M
Net income applicable to common shares 988.00M 866.00M 850.00M 942.00M 1988.00M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 16225.00M 16153.00M 14022.00M 12837.00M 13611.00M
Intangible assets 1636.00M 1763.00M 1166.00M 1092.00M 1167.00M
Earning assets - - - - -
Other current assets 361.00M 351.00M 286.00M 196.00M 223.00M
Total liab 8939.00M 9257.00M 7604.00M 6830.00M 7049.00M
Total stockholder equity 7170.00M 6778.00M 6307.00M 5893.00M 6444.00M
Deferred long term liab - - - - -
Other current liab - 945.00M 852.00M 1072.00M 1243.00M
Common stock 2.00M 2.00M 2.00M 2.00M 2.00M
Capital stock 2.00M 2.00M 2.00M 2.00M 2.00M
Retained earnings 9994.00M 9360.00M 8825.00M 8290.00M 7649.00M
Other liab - - - 812.00M 792.00M
Good will 8945.00M 8856.00M 7733.00M 7220.00M 7095.00M
Other assets 270.00M 255.00M 198.00M 144.00M 163.00M
Cash 420.00M 549.00M 686.00M 315.00M 872.00M
Cash and equivalents 420.00M 549.00M 686.00M 315.00M 872.00M
Total current liabilities 2278.00M 2169.00M 1815.00M 1551.00M 1753.00M
Current deferred revenue - - 516.00M - -
Net debt 6499.00M 6538.00M 4812.00M 4307.00M 3785.00M
Short term debt 678.00M 937.00M 585.00M 155.00M 153.00M
Short long term debt 707.00M 764.00M 432.00M 2.00M 2.00M
Short long term debt total 6919.00M 7087.00M 5498.00M 4622.00M 4657.00M
Other stockholder equity -2799.00000M -2496.00000M -2506.00000M -2378.00000M -1193.00000M
Property plant equipment 2860.00M 2764.00M 2418.00M 2351.00M 2304.00M
Total current assets 2378.00M 2392.00M 2372.00M 1898.00M 2741.00M
Long term investments 136.00M 123.00M 135.00M 132.00M 141.00M
Net tangible assets - - - -1853.00000M -1818.00000M
Short term investments - - - - -
Net receivables 1408.00M 1304.00M 1210.00M 1195.00M 1438.00M
Long term debt 5167.00M 5615.00M 4410.00M 3978.00M 4010.00M
Inventory 189.00M 188.00M 190.00M 192.00M 208.00M
Accounts payable 1600.00M 287.00M 378.00M 324.00M 357.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 37.00M 39.00M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -27.00000M -88.00000M -14.00000M -21.00000M -14.00000M
Additional paid in capital - - - - -
Common stock total equity - - - 2.00M 2.00M
Preferred stock total equity - - - - -
Retained earnings total equity - - - 8290.00M 7649.00M
Treasury stock - - - -4673.00000M -3453.00000M
Accumulated amortization - - - - -
Non currrent assets other 270.00M 255.00M 198.00M 144.00M 163.00M
Deferred long term asset charges - - - - -
Non current assets total 13847.00M 13761.00M 11650.00M 10939.00M 10870.00M
Capital lease obligations 711.00M 708.00M 656.00M 642.00M 645.00M
Long term debt total 5167.00M 5615.00M 4410.00M 3978.00M 4010.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -2548.00000M -1121.00000M -543.00000M 752.00M
Change to liabilities - - - -180.00000M 35.00M
Total cashflows from investing activities -631.00000M -2548.00000M -1061.00000M -543.00000M 21.00M
Net borrowings -602.00000M 1543.00M 748.00M -2.00000M -2.00000M
Total cash from financing activities -1388.00000M 1084.00M 160.00M -1732.00000M -2540.00000M
Change to operating activities - - - 53.00M -9.00000M
Net income 1046.00M 921.00M 908.00M 1015.00M 2080.00M
Change in cash -129.00000M -137.00000M 371.00M -557.00000M -286.00000M
Begin period cash flow 549.00M 686.00M 315.00M 872.00M 1158.00M
End period cash flow 420.00M 549.00M 686.00M 315.00M 872.00M
Total cash from operating activities 1886.00M 1334.00M 1272.00M 1718.00M 2233.00M
Issuance of capital stock - - - - -
Depreciation 570.00M 493.00M 439.00M 437.00M 408.00M
Other cashflows from investing activities -3.00000M 41.00M -42.00000M -139.00000M 424.00M
Dividends paid 353.00M 331.00M 314.00M -305.00000M -309.00000M
Change to inventory - - - - -20.00000M
Change to account receivables -106.00000M -71.00000M -15.00000M 246.00M 81.00M
Sale purchase of stock -450.00000M -151.00000M -275.00000M -1408.00000M -2199.00000M
Other cashflows from financing activities -62.00000M 23.00M 1.00M -17.00000M -159.00000M
Change to netincome - - - 147.00M -257.00000M
Capital expenditures 527.00M 425.00M 408.00M 404.00M 403.00M
Change receivables - - - 246.00M 81.00M
Cash flows other operating - - - 53.00M -323.00000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -557.00000M -286.00000M
Change in working capital 50.00M -201.00000M -145.00000M 119.00M 87.00M
Stock based compensation 88.00M 88.00M 77.00M 77.00M 79.00M
Other non cash items 27.00M 20.00M 42.00M 69.00M -364.00000M
Free cash flow 1359.00M 909.00M 864.00M 1314.00M 1830.00M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
DGX
Quest Diagnostics Incorporated		 3.21 1.63% 200.42 22.43 18.48 2.06 3.03 2.53 12.88
TMO
Thermo Fisher Scientific Inc		 12.60 2.68% 482.23 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 3.15 1.71% 186.68 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 2.93 2.21% 135.62 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 8.16 1.45% 569.33 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Quest Diagnostics Incorporated

500 Plaza Drive, Secaucus, NJ, United States, 07094

Key Executives

Name Title Year Born
Mr. Stephen H. Rusckowski Exec. Chairman 1957
Mr. James E. Davis CEO, Pres & Director 1963
Ms. Catherine T. Doherty Sr. VP of Regional Bus.es 1963
Mr. Sam A. Samad Exec. VP & CFO 1970
Mr. Michael J. Deppe VP, Corp. Controller & Chief Accounting Officer 1967
Ms. Gabrielle Wolfson Sr. VP and Chief Information & Digital Officer NA
Mr. Shawn C. Bevec VP of Investor Relations NA
Mr. Michael E. Prevoznik Sr. VP & Gen. Counsel 1962
Ms. Kristin Lee Wallace Esq. Sr. VP of Compliance NA
Mr. Gary D. Samuels Sr. VP & Chief Communications Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions